Causal effect of plasminogen activator inhibitor type 1 on coronary heart disease

Ci Song, Stephen Burgess, John D. Eicher, Christopher J. O'Donnell, Andrew D. Johnson, Jie Huang, Maria Sabater-Lleal, Folkert W. Asselbergs, David Tregouet, So Youn Shin, Jingzhong Ding, Jens Baumert, Tiphaine Oudot-Mellakh, Lasse Folkersen, Nicholas L. Smith, Scott M. Williams, Mohammad A. Ikram, Marcus E. Kleber, Diane M. Becker, Vinh TruongJosyf C. Mychaleckyj, Weihong Tang, Qiong Yang, Bengt Sennblad, Jason H. Moore, Frances M.K. Williams, Abbas Dehghan, Günther Silbernagel, Elisabeth M.C. Schrijvers, Shelly Smith, Mahir Karakas, Geoffrey H. Tofler, Angela Silveira, Gerjan J. Navis, Kurt Lohman, Ming Huei Chen, Annette Peters, Anuj Goel, Jemma C. Hopewell, John C. Chambers, Danish Saleheen, Per Lundmark, Bruce M. Psaty, Rona J. Strawbridge, Bernhard O. Boehm, Angela M. Carter, Christa Meisinger, John F. Peden, Aaron R. Folsom, Saonli Basu, CHARGE Consortium Hemostatic Factor Working Group, ICBP Consortium, CHARGE Consortium Subclinical Working Group

Research output: Contribution to journal › Article › peer-review

89 Scopus citations

Fingerprint

Dive into the research topics of 'Causal effect of plasminogen activator inhibitor type 1 on coronary heart disease'. Together they form a unique fingerprint.

Medicine & Life Sciences